[
    [
        {
            "time": "2023-01-01",
            "original_text": "Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls",
            "features": {
                "keywords": [
                    "Earnings Beat",
                    "Operating Margin",
                    "Falls"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Amedisys (AMED) Q1 Earnings Beat, Operating Margin Falls",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up",
            "features": {
                "keywords": [
                    "Earnings Lag",
                    "Operating Margin",
                    "Up"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "QIAGEN (QGEN) Q1 Earnings Lag Estimates, Operating Margin Up",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates",
            "features": {
                "keywords": [
                    "Earnings",
                    "Revenues",
                    "Top Estimates"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View",
            "features": {
                "keywords": [
                    "Beats",
                    "Withdraws View"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Bio-Rad (BIO) Beats Q1 Earnings Estimates, Withdraws View",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "Exact Sciences (EXAS) Q1 Earnings Fall Y/Y, Margin Expands",
            "features": {
                "keywords": [
                    "Earnings Fall",
                    "Margin Expands"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "diagnostics"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Exact Sciences (EXAS) Q1 Earnings Fall Y/Y, Margin Expands",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1",
            "features": {
                "keywords": [
                    "Earnings",
                    "Revenues",
                    "Beat Estimates"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates",
            "features": {
                "keywords": [
                    "Earnings",
                    "Revenues",
                    "Top Estimates"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "medical devices"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Becton Dickinson (BDX) Q2 Earnings and Revenues Top Estimates",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "Bristol Myers sees 2020 earnings holding despite coronavirus pandemic",
            "features": {
                "keywords": [
                    "earnings holding",
                    "coronavirus pandemic"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Bristol Myers sees 2020 earnings holding despite coronavirus pandemic",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-01-01",
            "original_text": "Express Scripts 'Parachute' to cap prescription costs for those hit by coronavirus turmoil",
            "features": {
                "keywords": [
                    "Parachute",
                    "prescription costs",
                    "coronavirus turmoil"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Express Scripts 'Parachute' to cap prescription costs for those hit by coronavirus turmoil",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]